The Role of IP in Mitigating Blood Culture Contamination
The Role of IP in Mitigating Blood Culture Contamination
0.00

The Role of the Infection Preventionist in Mitigating Blood Culture Contamination and False-Positive CLABSI

Wednesday, August 18 at 1 PM ET

Traditional interventions to reduce blood culture contamination, such as ongoing training, education, and manual waste tubes, cannot address the skin and skin plug contamination and have shown only modest and unsustainable reductions in contamination rates. Thirty-five to 50% of positive blood culture results indicating sepsis are false positives that resulted from touchpoint contamination and/or skin and skin plug contamination at the time of collection. These false-positive sepsis results confound clinical decisions regarding antibiotic therapy, including selection and de-escalation of broad-spectrum antibiotic treatment.

For the average-sized hospital, this means:

  1. 300 or more patients may be adversely impacted by false-positive blood cultures every year in the emergency department (ED) alone
  2. These patients are often treated with unnecessary antibiotics with attendant risks of secondary infection such as C. difficile, multidrug-resistant organisms (MDROs), and other antibiotic-associated complications
  3. Unnecessary laboratory workflow burden
  4. An estimated $1 million or more in avoidable costs

This webinar will review a case study of Stanford Health Care to demonstrate the profound clinical and financial impact that blood culture contamination and false-positive CLABSIs have on patient care. The case study will demonstrate how they reduced rates as low as 0.0% for false-positive blood culture contamination and false-positive CLABSIs and sustained this impactful improvement for 10 months using an evidence-based technology solution.

Speaker: Lucy Tompkins, MD, PhD
Lucy Becker Professor of Medicine, Division of Infectious Diseases and Geographic Medicine, Professor of Microbiology and Immunology
Stanford University Hospital

Speaker: Barb DeBaun, RN, MSN, CIC
Improvement Advisor
Cynosure Health

By registering for this webinar you are agreeing to be contacted by APIC industry partner: Magnolia Medical Technologies
 
vProductThumbnailvProductTitlevProductCodevMemberPricevStandardPricevProductCategoryvProductStatusvProductKitvProductOtherDescription
/images/Products/00000000-0000-0000-0000-000000000000_10459.JPGThe Role of IP in Mitigating Blood Culture ContaminationWB-2108180.000.00WEBINARSAFalse